R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 52.10
-0.65 (-1.23%)
At close: Sep 2, 2026
R&G PharmaStudies Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 939.31 | 851.01 | 744 | 721.37 | 637.52 | 608.43 | |
Revenue Growth | 26.14% | 14.38% | 3.14% | 13.15% | 4.78% | 25.59% |
Cost of Revenue | 644.2 | 555.36 | 468.08 | 434.34 | 402.62 | 375.25 |
Gross Profit | 295.11 | 295.64 | 275.92 | 287.04 | 234.9 | 233.17 |
Selling, General & Admin | 101.42 | 102 | 91.29 | 94.45 | 75.34 | 71.85 |
Research & Development | 65.2 | 61.97 | 56.83 | 52.86 | 49.99 | 41.19 |
Other Operating Expenses | 3.88 | 3.98 | 3.39 | 3.76 | 3.01 | 3.43 |
Operating Expenses | 171.66 | 173.13 | 154.88 | 155.93 | 131.92 | 124.02 |
Operating Income | 123.45 | 122.51 | 121.05 | 131.11 | 102.98 | 109.15 |
Interest Expense | -1.25 | -2.86 | -3.44 | -0.6 | -0.67 | -0.58 |
Interest & Investment Income | 14.61 | 21.25 | 23.17 | 34.6 | 15.04 | 5.46 |
Currency Exchange Gain (Loss) | -2.9 | -3.47 | 1.72 | 1.38 | 5.73 | -1.34 |
Other Non Operating Income (Expenses) | -11.16 | -0.38 | -1.79 | -0.35 | -0.58 | -0.41 |
EBT Excluding Unusual Items | 122.76 | 137.05 | 140.7 | 166.14 | 122.5 | 112.28 |
Gain (Loss) on Sale of Investments | 9 | 10.95 | 11.28 | 3.98 | 0.91 | -2.1 |
Gain (Loss) on Sale of Assets | -0.01 | -0.01 | -0.07 | -0.02 | -0.02 | -0.02 |
Asset Writedown | -2.87 | - | - | - | - | - |
Other Unusual Items | 6.09 | 7.16 | 5.87 | 12.37 | 5.5 | 3.44 |
Pretax Income | 134.98 | 155.15 | 157.79 | 182.47 | 128.89 | 113.6 |
Income Tax Expense | 12.86 | 16.85 | 16 | 19.61 | 14.75 | 13.24 |
Earnings From Continuing Operations | 122.12 | 138.29 | 141.79 | 162.86 | 114.13 | 100.35 |
Minority Interest in Earnings | -1.87 | -1.39 | -1.57 | -0.33 | -0.69 | -1.12 |
Net Income | 120.25 | 136.9 | 140.22 | 162.53 | 113.45 | 99.24 |
Net Income to Common | 120.25 | 136.9 | 140.22 | 162.53 | 113.45 | 99.24 |
Net Income Growth | -15.81% | -2.37% | -13.73% | 43.27% | 14.32% | 18.37% |
Shares Outstanding (Basic) | 96 | 96 | 95 | 96 | 82 | 72 |
Shares Outstanding (Diluted) | 96 | 96 | 95 | 96 | 82 | 72 |
Shares Change | 1.20% | 0.36% | -0.64% | 16.78% | 14.43% | -0.38% |
EPS (Basic) | 1.25 | 1.43 | 1.47 | 1.69 | 1.38 | 1.38 |
EPS (Diluted) | 1.25 | 1.43 | 1.47 | 1.69 | 1.38 | 1.38 |
EPS Growth | -16.81% | -2.72% | -13.17% | 22.68% | -0.09% | 18.82% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 45.81 | 94.93 | 134.78 | 172.68 | 109.64 | 76.29 |
Free Cash Flow Per Share | 0.48 | 0.99 | 1.41 | 1.80 | 1.33 | 1.06 |
Dividend Per Share | 0.160 | 0.160 | 0.160 | 0.200 | 0.156 | - |
Dividend Growth | 0% | 0% | -20.00% | 27.96% | - | - |
Gross Margin | 31.42% | 34.74% | 37.09% | 39.79% | 36.85% | 38.32% |
Operating Margin | 13.14% | 14.40% | 16.27% | 18.18% | 16.15% | 17.94% |
Profit Margin | 12.80% | 16.09% | 18.85% | 22.53% | 17.79% | 16.31% |
Free Cash Flow Margin | 4.88% | 11.15% | 18.12% | 23.94% | 17.20% | 12.54% |
EBITDA | 137.41 | 129.32 | 144.37 | 153.73 | 110.43 | 135.31 |
EBITDA Margin | 14.63% | 15.20% | 19.40% | 21.31% | 17.32% | 22.24% |
D&A For EBITDA | 13.96 | 6.81 | 23.32 | 22.62 | 7.44 | 26.16 |
EBIT | 123.45 | 122.51 | 121.05 | 131.11 | 102.98 | 109.15 |
EBIT Margin | 13.14% | 14.40% | 16.27% | 18.18% | 16.15% | 17.94% |
Effective Tax Rate | 9.53% | 10.86% | 10.14% | 10.75% | 11.45% | 11.66% |
Revenue as Reported | 471.34 | 851.01 | 744 | 721.37 | 637.52 | 608.43 |
Advertising Expenses | - | - | - | - | - | 1.61 |